首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >New Insights into the Combined Burden of Type 2 Diabetes and Hypertension
【24h】

New Insights into the Combined Burden of Type 2 Diabetes and Hypertension

机译:对2型糖尿病和高血压的组合负担的新见解

获取原文
获取原文并翻译 | 示例
           

摘要

Hypertension and type 2 diabetes are very common medical conditions that often occur in combination. A large amount of clinical trial data has proven the significance of improving blood pressure (BP) in type 2 diabetic patients in order to prevent cardiovascular morbidity and mortality, diabetic nephropathy and end-stage renal disease. The goal BP for all type 2 diabetics should be below 130/80 mm Hg, and below 125/75 mm Hg in subjects with significant proteinuria. Most investigators agree that an-giotensin-converting enzyme inhibitors should be the first-line agents because of their cardioprotective effects. In the end, it may be that the specific drug choice has less overall importance than the actual attainment of adequate BP control. Treatment of hypertension in type 2 diabetics will often require multiple agents to achieve the goal BP.
机译:高血压和2型糖尿病是通常结合发生的非常常见的医疗状况。 大量临床试验数据已证明,为了防止心血管发病率和死亡率,糖尿病性肾病和终末期肾脏疾病,改善血压(BP)的重要性。 所有2型糖尿病患者的目标BP应低于130/80 mm Hg,并且患有明显蛋白尿的受试者的目标BP低于125/75 mm Hg。 大多数研究人员都同意,由于其心脏保护作用,因此转化酶的酶抑制剂应成为一线剂。 最后,可能的是,特定的药物选择的总体重要性比实际获得足够的BP控制的重要性较小。 2型糖尿病患者中高血压的治疗通常需要多种药物才能实现目标BP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号